Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01603303 · ClinicalTrials.gov registry record · Phase 2
Preventing Sexual Dysfunction With Aromatase Inhibitors
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 187
- Enrollment target
NCT01603303: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01603303 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 187 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01603303, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 187 participants
- Enrollment target
Study Summary
Aromatase inhibitors (AIs) are used to try to stop breast cancer from forming or returning after treatment in women who are in menopause and who had breast cancer that was sensitive to the hormone estrogen. The goal of this study is to learn if it is possible to prevent some AI side effects, particularly problems with vaginal dryness and pain during sexual activity. Researchers also want to compare 2 new vaginal moisturizers to see if using them regularly helps women avoid vaginal dryness. Researchers want to see if preventing these side effects will decrease the number of women who stop taking AIs due to the side effects they cause.
Interventions
- BEHAVIORAL Questionnaires
- OTHER Education Materials
- OTHER Luvena
- OTHER Hyalo-Gyn
- OTHER Vaginal Lubricant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2012-12-05 |
| Est. Completion | 2017-08-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01603303
The ClinicalTrials.gov registry entry for NCT01603303 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Questionnaires is the first listed.
NCT01603303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01603303 about?
NCT01603303 is a clinical study titled "Preventing Sexual Dysfunction With Aromatase Inhibitors". Aromatase inhibitors (AIs) are used to try to stop breast cancer from forming or returning after treatment in women who are in menopause and who had breast cancer that was sensitive to the hormone estrogen. The goal of this study is to learn if it is possible to prevent some AI side effects, partic...
What is the current status of trial NCT01603303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2012-12-05. Estimated completion is 2017-08-11.
What interventions are being tested in trial NCT01603303?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Education Materials (OTHER), Luvena (OTHER), Hyalo-Gyn (OTHER), Vaginal Lubricant (OTHER).
Who is sponsoring clinical trial NCT01603303?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.